A r t i c l e s
, the most commonly used measure of kidney function. In addition, CKD causes substantial financial expenditures in the US 4 , with similar trends expected globally 5 .
Despite the increasing prevalence of CKD, our understanding of its underlying risk factors and pathophysiological mechanisms remains incomplete 5 . Hypertension and diabetes are major risk factors for CKD 6 . However, the marked variability in the development of CKD in individuals with hypertension and diabetes demonstrates that additional underlying factors contribute to its etiology 7 . In particular, studies have consistently demonstrated important genetic contributions to estimated glomerular filtration rate (eGFR), CKD and ESRD 8, 9 . Using genome-wide association, we recently identified susceptibility variants for renal function and CKD at UMOD, SHROOM3 and STC1 loci in nearly 20,000 individuals 10 . Together, SNPs at these loci explain only 0.43% of the variance in eGFR 10 , suggesting that additional loci remain to be identified.
We performed a genome-wide association meta-analysis in 67,093 study participants of European ancestry from 20 predominantly population-based cohorts within the CKDGen consortium, which was followed by independent replication of our findings in 22,982 individuals of European ancestry. We analyzed GFR estimated from serum creatinine by the Modification of Diet in Renal Disease (MDRD) Study equation (eGFRcrea) as well as CKD. To discriminate true susceptibility loci for renal function from those related to creatinine production and secretion, we used GFR estimated from a second serum marker of kidney function, cystatin c (eGFRcys). Table 2 summarizes information for the 28 genomic loci that contained at least one genome-wide significant SNP association (P < 5 × 10 −8 ) for any of the three renal traits; the SNP with the lowest P value at each locus (lead SNP) is shown. In addition to confirming 5 known loci 10 , we identified 23 new loci containing genome-wide significant SNPs (P values between 4.5 × 10 −8 and 3.8 × 10 −12 ); 20 SNPs were identified in association with eGFRcrea, 2 SNPs with CKD and 1 SNP with eGFRcys. Of note, rs7805747 in PRKAG2 was identified in discovery analyses for both eGFRcrea and CKD, as was the known lead SNP at the UMOD locus. Figure 1a shows the genome-wide −log 10 P value plot from stage 1 discovery association analyses for eGFRcrea, Figure 1b the plot for CKD and Figure 1c the plot for eGFRcys. The respective quantile-quantile plots are presented in Supplementary Figure 1 . Study-specific and median imputation quality for the lead SNPs can be found in Supplementary Table 2 .
RESULTS

Study samples
Meta-analysis in CKDGen stage 1 discovery cohorts
Corroborating evidence with eGFRcys
Because serum creatinine concentration is influenced both by renal function and by creatinine production or secretion, we used eGFRcys as a second measure of renal function to help distinguish between true renal function loci and loci that control creatinine production or secretion. Thus, of the 23 newly discovered loci, 16 were classified as related to renal function based on a direction-consistent association to eGFRcys with P < 0.05 ( Table 2 and Supplementary Table 3) , and 7 were classified as loci likely related to creatinine metabolism. Figure 2 shows comparisons, for each of the 23 genome-wide significant loci and the 5 known findings, of the magnitude of association with eGFRcrea as compared to eGFRcys. Of the suspected creatinine metabolism SNPs, all were associated with serum creatinine concentrations (with P values ranging from 5.6 × 10 −7 to 1.6 × 10 −21 ). One SNP, rs653178 at the ATXN2 locus, was identified primarily in association with eGFRcys.
Stage 2 replication of genome-wide significant discovery findings
The lead SNP at each of the 20 new loci for eGFRcrea, the 2 loci for CKD and the new locus for eGFRcys were evaluated for independent replication in stage 2 analyses with their associated discovery Chr., chromosome; NA, known loci were not replicated in additional study samples.
a The minor allele based on sample size-weighted mean allele frequency in the discovery cohorts is modeled. b Only rs12917707 at the UMOD locus showed significant heterogeneity. c Results of eGFRcys from discovery and replication combined. d SNP also significantly associated with at least one other kidney trait at P < 5 × 10 −8 . e SNP rs7422339 has changed the SNP identifier in the latest dbSNP release: current name is rs1047891. For ATXN2, the P value for eGFRcrea from stage 1 combined with stage 2 is 0.0005. Genes nearby were based on RefSeq genes (build 36). The gene closest to the SNP is listed first and is in boldface if the SNP is located within the gene.
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trait. After meta-analysis of stage 1 discovery and stage 2 replication results, the associations for all but three SNPs (rs16864170 at SOX11, rs1933182 at SYPL2 and rs4014195 at RNASEH2C) gained significance ( Table 2) . Additionally, 16 of these 20 SNPs also showed a significant association in the replication samples alone (one-sided P < 0.0025 for eGFRcrea, P < 0.025 for CKD and P < 0.05 for eGFRcys; Table 2 ). Thus, after integrating evidence for replication with association results for eGFRcys, we identified 13 replicated loci for renal function and 7 replicated loci likely related to creatinine metabolism. Of note, rs653178 at the ATXN2 locus, which was identified primarily in association with eGFRcys, was also associated with eGFRcrea in the combined discovery and replication results. Regional association plots for all replicated loci related to renal function are shown in Supplementary Figure 2 .
Of the SNPs that were validated by stage 2 replication and were also associated with eGFRcys, several lie in regions containing genes that can be linked to renal function and/or renal disease (ALMS1, DAB2, SLC34A1, PRKAG2, VEGFA, DACH1 and SLC7A9). These genes, together with the pleiotropic genes GCKR and ATXN2-SH2B3, are highlighted in Box 1. The remaining newly discovered renal function loci mapped to regions containing genes such as TFDP2, PIP5K1B, UBE2Q2 and LASS2. In spite of a lack of clear biological connection to renal function at these loci, findings were consistent across eGFRcrea, CKD and eGFRcys analyses. More information on these and other genes contained in the newly identified associated regions is shown in Supplementary Table 4 .
Of the 20 SNPs that replicated, the remaining 7 SNPs were not associated with eGFRcys and hence were considered as likely creatinine production or secretion loci (CPS1, SLC22A2, TMEM60, WDR37, SLC6A13, WDR72 and BCAS3). More information on these loci is presented in Supplementary Table 4 .
SNPs associated with eGFRcrea are also associated with CKD The majority of the 13 validated renal function loci were also nominally associated with CKD (Table 3) , underscoring how the study of intermediate phenotypes can provide insight into disease-based traits. The odds ratios associated with CKD for each additional copy of the minor allele ranged from 0.93 to 1.19, and minor allele frequencies ranged from 0.20 to 0.50.
Stratified analyses and measures of clinical relevance
Because diabetes mellitus and hypertension are major risk factors for kidney disease, we investigated the association of the known and the replicated renal function loci with eGFRcrea stratified by diabetes or hypertension status in the discovery cohorts (Supplementary Table 5 ). None of the newly discovered, replicated renal function SNPs reported in Table 2 differed significantly across strata of diabetes and hypertension (P < 5.6 × 10 −3 , Bonferroni-corrected α of 0.1 for 18 tests).
The 13 confirmed and the three previously identified renal function loci account for 1.4% of the variation in eGFRcrea. We computed a genetic risk score using all 16 validated renal loci (13 new and 3 known). Across all categories of the genetic risk score, the mean eGFRcrea ranged from 94.0 ml/min/1.73 m 2 (in individuals with a risk score <9.5) to 77.1 ml/min/1.73 m 2 (in individuals with a risk score >25.5), and CKD prevalence ranged from 4.3% to 27.9%, respectively (Fig. 3) .
Analyses of expression-associated SNPs (eSNPs)
Expression SNP analyses can provide evidence for the presence of functional variants at identified genomic risk loci and can assist in the prioritization of candidate genes in the associated regions. We therefore focused on SNPs previously identified in genome-wide studies as being significantly related to gene expression in liver (n = 3,322) 11 , lymphocytes (n = 29,094) 12 or lymphoblastoid cell lines (n = 10,823) 13 . These eSNPs were then evaluated for their association with eGFRcrea, CKD and eGFRcys from the discovery analysis. Nine of the 20 newly discovered susceptibility loci identified for eGFRcrea Loci possibly related to renal function Creatinine production or secretion loci Cystatin c production or secretion loci A r t i c l e s (7 out of 13 renal function loci) contained 1 or more significant eSNPs in at least 1 of the expression tissues queried ( Table 4 ). In addition, three of the previously identified loci (in SHROOM3, GATM and CST3) also contained at least one significant eSNP. The correlation (r 2 ) between the lead SNP and the significant eSNP at each locus in the strongest linkage disequilibrium (LD) to the lead SNP ranged from 0.01 (in FBXO22) to >0.9 (in DAB2 and GCKR; Table 4 ). The lead SNP in GCKR (rs1260326), a nonsynonymous coding variant, was significantly associated with gene expression of the neighboring IFT172 gene (Table 4) . Further, the eSNP data supports SLC7A9 as the important gene at the susceptibility locus at chromosome 19, as well as ALMS1 at the susceptibility locus on chromosome 2p13, as an eSNP in perfect LD (r 2 = 1) with rs13538 in the HapMap CEU population is significantly associated with ALMS1 transcript expression in lymphocytes. All eSNPs with significant association with at least one renal trait are listed in Supplementary Table 6 .
Secondary analyses based on false discovery rate (FDR)
To further identify genomic loci for kidney function and disease, we conducted secondary analyses to identify SNPs that did not reach genome-wide significance but which were associated with eGFRcrea or CKD at an FDR of 0.05 (P < 4.8 × 10 −6 ). After exclusion of all SNPs within 1 Mb of a genome-wide significant SNP, nine additional loci for eGFRcrea were identified, four of which were also associated with eGFRcys (Supplementary Table 7) . We also compared the loci identified by FDR with those from the eSNP analysis and identified three regions of overlap. The r 2 between each FDR-identified SNP and the eSNP in highest LD with that SNP ranged from 0.18 (in ARL15) to 1.0 (in CASP9 and CRKRS), providing further support for these genomic regions as loci of interest. Based on known biology, PARD3B and CASP9 are particularly interesting genes emerging from FDR analyses. PARD3B-encoded protein is important in establishing cell polarity and localizes to tight junctions of epithelial cells 14 ; it shows highest expression in fetal and adult kidney. Caspase-9 is involved in the growth of metanephroi in the developing kidney 15 .
DISCUSSION
Our principal findings are fourfold. We have identified 20 new replicated loci associated with eGFR and CKD. Of these, 13 are likely to be involved in renal function and in susceptibility to CKD, whereas 7 are likely to be associated with creatinine production or secretion. In aggregate, the 13 new renal function loci discovered here combined with the 3 previously identified renal function loci account for 1.4% of the variation in eGFRcrea. We demonstrate altered gene expression associated
BOX 1 Genes of special interest with respect to kidney function and disease at newly discovered susceptibility loci
Genes highlighted here have previously been linked to renal disease or to traits associated with renal function. Further genes contained in associated regions but not known to be related to renal disease are discussed in supplementary table 4.
SLC7A9.
SLC7A9 encodes an amino acid transporter expressed in renal proximal tubule cells; mutations in SLC7A9 cause cystinuria type B (MIM#220100) 22 .
Individuals with cystinuria excrete elevated amounts of amino acids, resulting in the formation of cystine stones in the urinary tract and cystine-crystal plugging of Bellini's ducts, which can cause interstitial fibrosis and, thus, chronic renal insufficiency 23 . Slc7a9-deficient mice show tubular and pelvic dilatation, tubular necrosis and chronic interstitial nephritis 24 .
SLC34A1. Mutations in SLC34A1 cause hypophosphatemic nephrolithiasis/osteoporosis (MIM#612286) 25 . SLC34A1 encodes the type IIa Na-Pi cotransporter, which is exclusively expressed in kidney and is located in the brush border of renal proximal tubular cells, where it mediates reuptake of inorganic phosphate 26 . VEGFA. VEGFA encodes vascular endothelial growth factor A, which has roles in angiogenesis and vascular permeability 35 . Renal podocytes produce large amounts of VEGFA, which is essential for glomerulogenesis and glomerular filtration barrier formation in animal models 35 . VEGFA has been reported to affect ureteric bud growth during embryogenesis and hence may affect nephron numbers 36 . The associated region maps downstream of VEGFA and does not include other genes.
ALMS1. Mutations in
GCKR.
The product of GCKR inhibits hepatic glucokinase 37 . Common variants in GCKR, and specifically the missense SNP rs1260326 (which yields a P446L substitution), are associated with a variety of human traits in genetic association studies, including serum triglycerides, fasting glucose, C-reactive protein and uric acid as well as susceptibility to type 2 diabetes (see URLs), highlighting the pleiotropy of this locus. eSNP analyses point to a role for the neighboring IFT172, which is involved in the formation of primary cilia 38 .
PRKAG2.
Rare PRKAG2 variants cause a form of heart disease featuring hypertrophic cardiomyopathy and the Wolff-Parkinson-White syndrome 39, 40 and can sometimes cause enlarged kidneys 41 . Studies in transgenic mice indicate that these mutations cause a glycogen-storage disease of the heart 40 . Several other hereditary glycogen storage diseases present with renal pathology, such as renal tubular dysfunction 42 . The lead SNP identified in the region lies upstream of PRKAG2.
DACH1
. DACH1 encodes Dachshund homolog 1, a transcription factor with a role in organogenesis; our data implicate a 100-kb region within this gene. It is expressed in adult human kidney as well as in developing mouse kidney, specifically glomerular podocytes and tubular epithelial cells 43 . DACH1 may have a role in the development of the Mullerian duct 44 . DACH1 is part of the genetic network including SIX and EYA 45 , mutations in which cause brachio-oto-renal syndrome 46 .
ATXN2. ATXN2 and the neighboring gene SH2B3 are located within a large (>1 Mb) LD block. The eGFRcys-associated SNP rs653178 has also been reported in genome-wide association studies of blood pressure 47 and celiac disease 48 . This SNP is perfectly correlated (r 2 = 1) with a missense SNP in SH2B3 (rs3184504, resulting in the substitution W262R; P = 1 × 10 −7 in our study), a variant that has been identified in genetic association studies of type 1 diabetes 49 , eosinophil counts and myocardial infarction 50 .
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with SNPs at several of the identified loci, providing potential functional insight. Lastly, we provide suggestive evidence for an additional nine eGFRcrea-associated loci using a false discovery rate metric; at least four of these are suspected to be related to renal function. These findings extend previous knowledge of common genetic variation related to indices of renal function. We have confirmed our prior findings, which identified common risk variants at the UMOD, SHROOM3 and STC1 loci as well as at two positive control loci (GATM and CST) 10 . We now use predominantly populationbased studies to identify variation at 13 new loci not previously associated with renal function. We also uncovered seven loci likely influencing creatinine production or secretion. This underscores the need to separate genetic loci that affect concentrations of a biomarker independent of underlying disease processes from those that reflect disease association. Similar to what we have previously reported 10 , we identified many more associations with eGFRcrea as compared to CKD. Nonetheless, nominal associations with CKD were identified for most of the SNPs associated with renal function, showing that genetic variants associated with normal variation in eGFRcrea are also associated with the clinically important CKD.
Our findings indicate how genome-wide association studies (GWAS) can uncover the genetic underpinnings of complex human traits and diseases. First, they provide information about the allelic architecture of known risk loci for genetic kidney diseases. Rare mutations in SLC7A9, SLC34A1, ALMS1 and UMOD are known to cause monogenetic diseases that feature a renal phenotype, underscoring the importance of common genetic susceptibility variants in these genes. This phenomenon is also observed for other complex traits and diseases; approximately 20% of loci discovered in GWAS for a variety of complex traits are known to also harbor mutations that cause monogenic diseases 16 .
Second, our findings provide information about the genomic location of genetic variants associated with renal indices. Eighty percent (20 out of 25) of the SNPs identified in our discovery analyses are located in genes or are contained within a region spanning 3.7 kb upstream of genes, and three are nonsynonymous coding variants. This is in agreement with recent studies that reported an enrichment of trait-associated variants identified in GWAS at nonsynonymous coding sites and a depletion of trait-associated variants in intergenic regions when compared to a random selection of variants on genotyping arrays 17, 18 .
Third, our replicated findings point toward several pathways and mechanisms in renal development and function. We identified common genetic variants in genes related to nephrogenesis (ALMS1, VEGFA and, potentially, DACH1), glomerular filtration barrier formation and podocyte function (DAB2, PARD3B and VEGFA), angiogenesis (VEGFA), solute transport (SLC7A9, SLC34A1) and metabolic functions of the kidney (PRKAG2 and, potentially, GCKR and LASS2). Several of the genes we identified can be linked to the role of primary cilia (ALMS1, GCKR-IFT172 and PARD3B); mutations in genes with roles in the development and function of primary cilia are known to cause hereditary genetic diseases of the kidney such as polycystic kidney disease and nephronophthisis 19 .
Similar to what has been observed previously, we identified modest effects of the risk alleles on eGFR and CKD. Taken together, these renal-function loci are associated with 1.4% of the variation in eGFRcrea. Nevertheless, we observed substantial gradation of CKD prevalence across the genetic risk score, indicating the potential clinical relevance of a combination of risk alleles of individually small effects. Common disorders such as CKD may be thought of as the extremes of underlying polygenic quantitative traits 20 , and identifying determinants of the whole distribution may improve understanding of mechanisms important for renal development and CKD pathogenesis. OR, odds ratio; CKD, chronic kidney disease; Chr., chromosome.
a The minor allele based on sample size-weighted mean allele frequency in the discovery cohorts is modeled. b Results based on stage 1 discovery and stage 2 replication combined. Genes within 60 kb of the lead SNP were based on RefSeq genes (b36). The gene closest to the SNP is listed first and bold if the SNP is located within the gene. P values from the discovery screen are corrected for genomic control before and after meta-analysis. 
The strength of our analysis lies in our sample size of 67,093 subjects used in the discovery stage, which allowed us to uncover multiple loci despite their small effect size on eGFR and CKD. We restricted our analyses to predominantly population-based studies, thereby avoiding potential bias from using case-control samples 21 or from potential counter-regulating disease processes. We used several more methods, including FDR and eSNPs, to identify additional loci beneath the standard genome-wide threshold. To enable discrimination of loci associated with renal function from those associated with creatinine production and secretion, we used a separate complementary measure of glomerular filtration obtained from cystatin c.
Some limitations warrant mention. Our sample consists of participants of European ancestry only, and it is unknown whether these results will replicate in other ancestral groups. We used an indirect measure of GFR as estimated by the MDRD Study equation; the use of gold-standard measures of glomerular filtration is not feasible in this setting. Multiple other equations besides the MDRD Study equation exist to estimate GFR. We used eGFRcys to provide confirmatory evidence of which newly discovered loci were truly associated with renal function. Loci that were not associated with eGFRcys were designated as presumptive creatinine production or secretion loci, but the smaller sample size with available cystatin c measures limited the power to confirm renal function loci. We may have falsely labeled some loci as unrelated to renal function based on the absence of an association with eGFRcys, particularly loci at WDR37 and WDR72, which showed association of borderline significance with eGFRcys. Further, the smaller sample size with available cystatin c measurements may explain our lack of ability to detect many new loci on a genome-wide basis for this analyte. Our eSNP results are based on expression datasets generated from liver tissue and lymphocytes; unfortunately, there are no expression databases generated from renal tissues available at the present time. Lastly, many regions of interest contained several genes each. For these regions, we were unable to identify which is the most likely gene to be related to the SNP association based on statistical evidence.
In summary, multiple common genetic variants are associated with indices of renal function, which highlights the role of specific genes in nephrogenesis, podocyte function, angiogenesis, solute transport and metabolic functions of the kidney.
URLs. Human genome-wide association studies, http://www.genome. gov/GWAstudies/.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. P values in bold are <1/n, with n being the number of eSNPs queried (3,322 for liver, 10,823 for lymphoblastoid cell lines (LCL) and 29,094 for lymphocytes).
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METhODS
Renal function indices. Serum creatinine and cystatin c were measured as detailed in the Supplementary Note. To account for between-laboratory variation across studies, serum creatinine was calibrated to the National Health and Nutrition Examination Study (NHANES) standards in all studies (including replication cohorts) as described previously 6, 10, 51 . Glomerular filtration rate based on serum creatinine (eGFRcrea) was estimated using the four-variable MDRD Study equation 52 . GFR based on cystatin c (eGFRcys) was estimated as eGFRcys = 76.7 × (serum cystatin c) −1.19 (ref. 53) . CKD was defined as eGFRcrea < 60 ml/min/1.73 m 2 according to National Kidney Foundation guidelines 54 . In all studies except FHS and ARIC, CKD was defined on the basis of a single measurement of serum creatinine at the baseline visit; FHS and ARIC used a cumulative definition of CKD based on serum creatinine measurements at several study visits (Supplementary Note).
Covariate definition. Diabetes was defined as fasting glucose ≥126 mg/dl, on the basis of pharmacologic treatment for diabetes or by self-report. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg or pharmacologic treatment for hypertension. All cohorts used these definitions except where stated differently in the Supplementary Note.
Genome-wide genotyping platforms and imputation. Genotyping was conducted as specified in Supplementary Table 1b and in the Supplementary Note. Each study conducted quality-control procedures on genotyped SNPs and then imputed to ~2.5 million HapMap SNPs, based on HapMap CEU samples. Imputed genotypes were coded using fractional counts between 0 and 2 according to the estimated number of copies of a specified allele. Study-specific details regarding sample sizes and study design, quality-control procedures and imputation can be found in Supplementary Table 1 .
Statistical methods for discovery stage. At the individual study level, GWAS of CKD and natural log-transformed eGFRcrea and eGFRcys levels were conducted using linear or logistic regression and assuming an additive genetic effect model, adjusting for age, sex and study site (where applicable) and accounting for relatedness where necessary. Imputation uncertainty was accounted for by using allele dosages. All studies provided data for eGFRcrea meta-analyses; participants in the FHS Third Generation and the Amish studies did not contribute to the CKD meta-analysis because of small numbers of CKD cases. Details regarding each discovery cohort can be found in the Supplementary Note. Fixed-effect meta-analyses of study-specific eGFRcrea, CKD and eGFRcys SNP-association results, using inverse-variance weighting, were performed using METAL (see URLs). Genomic control correction by calculating the lambda factor (λ) across all imputed SNPs 55 was applied at both the individual study level before meta-analysis (for studies with λ > 1) and after the meta-analysis of the overall results. SNPs with minor allele frequency < 1% were excluded. Heterogeneity was tested using Cochran's Q test; P < 0.00417 (0.1/24) indicated significant heterogeneity.
To indicate statistical significance, we used the standard threshold of P < 5 × 10 −8 , assuming 1 million independent SNPs. Among all SNPs with meta-analysis P values below this threshold for any of the three traits, we selected independent SNPs (defined by pairwise r 2 < 0.2) to represent each locus. Not more than one independent signal was identified per locus; therefore, only one genome-wide significant SNP per locus was put forward for replication.
Where not specified otherwise, R software was used for data management, statistical analyses and graphing 56 .
Replication analysis. Replication studies used the same phenotype definition, had either imputed in silico genome-wide SNP data or de novo genotyped data available, and conducted the same association analyses as discovery stage studies. Details regarding each replication cohort can be found in the Supplementary Note.
For all de novo genotyping (10,466 samples from KORA F3, KORA F4, SAPHIR and SAPALDIA), Assay Design v.3.1.2 and the iPLEX chemistry (Sequenom) was used at the MassARRAY system at the Helmholtz Zentrum. Ten percent of the spectra were checked by two independent trained persons, a process that yielded 100% concordance. SNPs rs13538 and rs10774021 failed Sequenom genotyping. Therefore, PCR genotyping of rs13538 was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems). Concordance for duplicate genotypes (5-10% in each study) was 94.3-100.0% (mean 99.1%). The mean call rate across all studies and SNPs was 98.8%, and the distribution of genotypes did not deviate from Hardy-Weinberg equilibrium (P > 0.001).
Study-specific replication results on the selected SNPs were combined using the same meta-analysis approach and software as in the discovery stage. First, meta-analysis was conducted by combining discovery and replication studies together and computing two-sided P values. Second, meta-analysis was conducted in the replication studies only, with one-sided P values being computed with regard to the effect direction found in the discovery stage. All replication cohorts contributed to the eGFRcrea replication; however, due to the small numbers of CKD cases, the following studies did not provide results for the CKD replication meta-analysis: Family Heart Study, SAPHIR and SPLIT. We considered a SNP as validated if the meta-analysis of all discovery and replication studies together yielded stronger association (smaller P values). We considered a SNP to show significant independent evidence when the one-sided P value in the replication stage alone met the following thresholds: P < 0.0025 (eGFRcrea), P < 0.025 (CKD) and P < 0.05 (eGFRcys), corresponding to a trait-specific Bonferroni correction.
Power estimation for replication used QUANTO (see URLs) 57 , assuming an additive genetic model. In discovery stage, we had 99.6% power to detect genetic factors on eGFR explaining 0.1% of the phenotypic variance based on the 5 × 10 −8 significance threshold. For independent replication using one-sided tests, we had 84.8% power to detect an effect size explaining 0.1% of the phenotypic variance based on 15,000 samples in the replication stage and correcting for the 23 SNPs tested.
Risk score analysis. The genetic risk score was created as an additive score by summing the dosages of the risk alleles each individual carried, where the risk allele was the allele associated with lower levels of eGFRcrea in the discovery meta-analysis. The score was based on information at 16 SNPs: the 13 replicated renal function SNPs and the lead SNP at each of the three already known renal disease loci (UMOD, SHROOM3 and STC1). To determine mean eGFRcrea and the proportion of individuals with CKD across categories of the risk score, the risk score was combined into categories spanning 1 unit and ranging from ≤9.5 to ≥25.5. Mean eGFRcrea in each risk score category was then determined by conducting an inverse variance weighted fixed-effects meta-analysis across the studies that contributed more than two observations to that risk score category. Similarly, the combined prevalence of CKD was determined by conducting an inverse-variance weighted fixed effects metaanalysis across studies that contributed more than two observations to the respective risk score category, where a Freeman-Tukey arcsine transformation was used to stabilize variance. eSNP analysis. A database of eSNPs was created from three publicly available datasets. The eSNPs represent SNPs significantly associated with gene expression in GWAS at a false-discovery threshold defined in the original reports for three tissues and that passed quality control in the meta-analysis of traits in this paper. The eSNP sources are as follows: liver (n = 3,322 SNPs) 11 , fresh lymphocytes (n = 29,094) 12 and lymphoblastoid cell lines (n = 10,823) 13 . The genomic control-corrected meta-analysis P values for each renal trait were compared for the predefined eSNP datasets against a correction threshold of 1/n, where n equals the number of eSNPs surveyed. The extent of LD between eSNPs below the correction threshold and the lead GWAS SNPs in the corresponding region was examined in the HapMap CEU population using SNAP 58 .
FDR analyses. Estimation of the FDR for association P values in the analysis of eGFR and CKD was performed using qvalue 59 software in R with default settings. The P values were derived from association statistics after twice correcting by genomic control (study specific and post meta-analysis). To evaluate the influence of LD on the identification of candidate loci by the FDR approach, we performed separate analyses in subsets of SNPs having reduced inter-SNP LD among the WGHS imputed genotypes as chosen by the variance
